Report Detail

Pharma & Healthcare Global anti-HA Antibody Market Growth 2018-2023

  • RnM2746905
  • |
  • 10 January, 2019
  • |
  • Global
  • |
  • 162 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called “antigens”). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Köhler – scientists at the Roche-funded Basel Institute for Immunology – who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological research and built the basis for the use of therapeutic antibodies in medicine and for the entire biotechnology industry.
In Vitro Diagnostics (IVD) are tests used to detect disease, infections and other medical conditions. The growing need of IVD testing arises due to increasing incidences of chronic and infectious diseases and growing geriatric population prone to immunological disorders. Moreover, increased application of personalized medicines and widespread knowledge of rare diseases are boosting the growth of IVD market. In the recent years, antibody used for IVD industry developed rapidly in China

According to this study, over the next five years the anti-HA Antibody market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global market share (sales and revenue) of key companies in anti-HA Antibody business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of anti-HA Antibody market by product type, application, key manufacturers and key regions and countries.

This study considers the anti-HA Antibody value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2013 to 2018, in Section 2.3; and forecast to 2023 in section 11.7.
IgM
IgG
IgA
Other
Segmentation by application: breakdown data from 2013 to 2018, in Section 2.4; and forecast to 2023 in section 11.8.
Therapeutic
Research
Diagnostic

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Johnson & Johnson
Merck
Novartis
AbbVie
Amgen
Pfizer
Bayer
Lilly
Bristol-Myers Squibb
GlaxoSmithKline
Biogen
AstraZeneca
Sanofi
Alexion Pharmaceuticals
Seattle Genetics

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global anti-HA Antibody consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of anti-HA Antibody market by identifying its various subsegments.
Focuses on the key global anti-HA Antibody manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the anti-HA Antibody with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of anti-HA Antibody submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.


Table of Contents

    2018-2023 Global anti-HA Antibody Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global anti-HA Antibody Consumption 2013-2023
        • 2.1.2 anti-HA Antibody Consumption CAGR by Region
      • 2.2 anti-HA Antibody Segment by Type
        • 2.2.1 IgM
        • 2.2.2 IgG
        • 2.2.3 IgA
        • 2.2.4 Other
      • 2.3 anti-HA Antibody Consumption by Type
        • 2.3.1 Global anti-HA Antibody Consumption Market Share by Type (2013-2018)
        • 2.3.2 Global anti-HA Antibody Revenue and Market Share by Type (2013-2018)
        • 2.3.3 Global anti-HA Antibody Sale Price by Type (2013-2018)
      • 2.4 anti-HA Antibody Segment by Application
        • 2.4.1 Therapeutic
        • 2.4.2 Research
        • 2.4.3 Diagnostic
      • 2.5 anti-HA Antibody Consumption by Application
        • 2.5.1 Global anti-HA Antibody Consumption Market Share by Application (2013-2018)
        • 2.5.2 Global anti-HA Antibody Value and Market Share by Application (2013-2018)
        • 2.5.3 Global anti-HA Antibody Sale Price by Application (2013-2018)

      3 Global anti-HA Antibody by Players

      • 3.1 Global anti-HA Antibody Sales Market Share by Players
        • 3.1.1 Global anti-HA Antibody Sales by Players (2016-2018)
        • 3.1.2 Global anti-HA Antibody Sales Market Share by Players (2016-2018)
      • 3.2 Global anti-HA Antibody Revenue Market Share by Players
        • 3.2.1 Global anti-HA Antibody Revenue by Players (2016-2018)
        • 3.2.2 Global anti-HA Antibody Revenue Market Share by Players (2016-2018)
      • 3.3 Global anti-HA Antibody Sale Price by Players
      • 3.4 Global anti-HA Antibody Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global anti-HA Antibody Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players anti-HA Antibody Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 anti-HA Antibody by Regions

      • 4.1 anti-HA Antibody by Regions
        • 4.1.1 Global anti-HA Antibody Consumption by Regions
        • 4.1.2 Global anti-HA Antibody Value by Regions
      • 4.2 Americas anti-HA Antibody Consumption Growth
      • 4.3 APAC anti-HA Antibody Consumption Growth
      • 4.4 Europe anti-HA Antibody Consumption Growth
      • 4.5 Middle East & Africa anti-HA Antibody Consumption Growth

      5 Americas

      • 5.1 Americas anti-HA Antibody Consumption by Countries
        • 5.1.1 Americas anti-HA Antibody Consumption by Countries (2013-2018)
        • 5.1.2 Americas anti-HA Antibody Value by Countries (2013-2018)
      • 5.2 Americas anti-HA Antibody Consumption by Type
      • 5.3 Americas anti-HA Antibody Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC anti-HA Antibody Consumption by Countries
        • 6.1.1 APAC anti-HA Antibody Consumption by Countries (2013-2018)
        • 6.1.2 APAC anti-HA Antibody Value by Countries (2013-2018)
      • 6.2 APAC anti-HA Antibody Consumption by Type
      • 6.3 APAC anti-HA Antibody Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe anti-HA Antibody by Countries
        • 7.1.1 Europe anti-HA Antibody Consumption by Countries (2013-2018)
        • 7.1.2 Europe anti-HA Antibody Value by Countries (2013-2018)
      • 7.2 Europe anti-HA Antibody Consumption by Type
      • 7.3 Europe anti-HA Antibody Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa anti-HA Antibody by Countries
        • 8.1.1 Middle East & Africa anti-HA Antibody Consumption by Countries (2013-2018)
        • 8.1.2 Middle East & Africa anti-HA Antibody Value by Countries (2013-2018)
      • 8.2 Middle East & Africa anti-HA Antibody Consumption by Type
      • 8.3 Middle East & Africa anti-HA Antibody Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.2 anti-HA Antibody Distributors
      • 10.3 anti-HA Antibody Customer

      11 Global anti-HA Antibody Market Forecast

      • 11.1 Global anti-HA Antibody Consumption Forecast (2018-2023)
      • 11.2 Global anti-HA Antibody Forecast by Regions
        • 11.2.1 Global anti-HA Antibody Forecast by Regions (2018-2023)
        • 11.2.2 Global anti-HA Antibody Value Forecast by Regions (2018-2023)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global anti-HA Antibody Forecast by Type
      • 11.8 Global anti-HA Antibody Forecast by Application

      12 Key Players Analysis

      • 12.1 Roche
        • 12.1.1 Company Details
        • 12.1.2 anti-HA Antibody Product Offered
        • 12.1.3 Roche anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.1.4 Main Business Overview
        • 12.1.5 Roche News
      • 12.2 Johnson & Johnson
        • 12.2.1 Company Details
        • 12.2.2 anti-HA Antibody Product Offered
        • 12.2.3 Johnson & Johnson anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.2.4 Main Business Overview
        • 12.2.5 Johnson & Johnson News
      • 12.3 Merck
        • 12.3.1 Company Details
        • 12.3.2 anti-HA Antibody Product Offered
        • 12.3.3 Merck anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.3.4 Main Business Overview
        • 12.3.5 Merck News
      • 12.4 Novartis
        • 12.4.1 Company Details
        • 12.4.2 anti-HA Antibody Product Offered
        • 12.4.3 Novartis anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.4.4 Main Business Overview
        • 12.4.5 Novartis News
      • 12.5 AbbVie
        • 12.5.1 Company Details
        • 12.5.2 anti-HA Antibody Product Offered
        • 12.5.3 AbbVie anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.5.4 Main Business Overview
        • 12.5.5 AbbVie News
      • 12.6 Amgen
        • 12.6.1 Company Details
        • 12.6.2 anti-HA Antibody Product Offered
        • 12.6.3 Amgen anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.6.4 Main Business Overview
        • 12.6.5 Amgen News
      • 12.7 Pfizer
        • 12.7.1 Company Details
        • 12.7.2 anti-HA Antibody Product Offered
        • 12.7.3 Pfizer anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.7.4 Main Business Overview
        • 12.7.5 Pfizer News
      • 12.8 Bayer
        • 12.8.1 Company Details
        • 12.8.2 anti-HA Antibody Product Offered
        • 12.8.3 Bayer anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.8.4 Main Business Overview
        • 12.8.5 Bayer News
      • 12.9 Lilly
        • 12.9.1 Company Details
        • 12.9.2 anti-HA Antibody Product Offered
        • 12.9.3 Lilly anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.9.4 Main Business Overview
        • 12.9.5 Lilly News
      • 12.10 Bristol-Myers Squibb
        • 12.10.1 Company Details
        • 12.10.2 anti-HA Antibody Product Offered
        • 12.10.3 Bristol-Myers Squibb anti-HA Antibody Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.10.4 Main Business Overview
        • 12.10.5 Bristol-Myers Squibb News
      • 12.11 GlaxoSmithKline
      • 12.12 Biogen
      • 12.13 AstraZeneca
      • 12.14 Sanofi
      • 12.15 Alexion Pharmaceuticals
      • 12.16 Seattle Genetics

      13 Research Findings and Conclusion

      Summary:
      Get latest Market Research Reports on anti-HA Antibody . Industry analysis & Market Report on anti-HA Antibody is a syndicated market report, published as Global anti-HA Antibody Market Growth 2018-2023. It is complete Research Study and Industry Analysis of anti-HA Antibody market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,660.00
      $5,490.00
      $7,320.00
      2,928.00
      4,392.00
      5,856.00
      3,418.44
      5,127.66
      6,836.88
      575,827.80
      863,741.70
      1,151,655.60
      305,207.40
      457,811.10
      610,414.80
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report